Issue 71

EXCLUSIVE: Novamind to host Phase II psilocybin trial

Novamind today announced it has been contracted by the Usona Institute to provide a research site for its Phase II clinical trial investigating psilocybin for major depressive disorder.

The FDA granted Breakthrough Therapy Designation to fast-track the study, with the regulator identifying that psilocybin-assisted therapy may offer a substantial clinical improvement over existing treatments.

In an exclusive interview about the announcement, PSYCH sat down with Dr Reid Robison, Chief Medical Officer at Novamind.

DEMAND GROWS FOR UK MINISTERS TO RECLASSIFY PSILOCYBIN

Crispin Blunt, Chair of the Conservative Drug Policy Reform Group, spoke with The Guardian on rescheduling psilocybin.

VICE: IT'S TIME TO START STUDYING THE DOWNSIDE OF PSYCHEDELICS

As interest in psychedelic medicine grows, so does the call to highlight adverse events in clinical trials and research.

BUSINESS AND INVESTMENT

Business Insider reviews Gwella’s functional mushroom product.

How psychedelics will impact mainstream product development.

Field Trip and Cerebral partner on ketamine-assisted therapy.

MINDCURE files patents for ibogaine mixtures.

Former Moderna VP joins MAPS PBC as COO.

PSYCH Symposium: London 2022

PSYCH Symposium enables industry leaders to connect and collaborate to expedite access to psychedelic healthcare across Europe.

There are now just two days left to secure Early Bird Tickets.

Secure your ticket today to connect with industry influencers, learn from the sector’s thought leaders and contribute to the future of psychedelics as medicine in Europe.

For speaking and partnership opportunities, please visit the website.

Ticket registration

SCIENCE AND RESEARCH

The evidence-based case for rescheduling psilocybin.

A narrative synthesis of research with 5-MeO-DMT.

Ketamine supports abstinence in patients with alcohol use disorder.

Can psychedelics provide a breakthrough in mental health?

Yale researchers study ketamine as a treatment for depression.

REGULATION AND LEGISLATION

The plan to reschedule psilocybin at the UN.

Oklahoma advances bill to study psychedelic compounds.

Zero-tolerance drug policies stop UK students seeking help.

Oregon residents interested in taking psilocybin for personal well-being.

Rhode Island lawmakers file drug decriminalisation bills.